J&J’s Opioid Reckoning Includes a Check for $230M

However, a statement released by Johnson & Johnson downplayed their involvement, noting that their two prescription painkillers accounted for less than 1% of the market. The statement noted that the settlement is “not an admission of liability or wrongdoing by the company,” said the statement,” and that its actions “relating to the marketing and promotion of important prescription pain medications were appropriate and responsible.” As part of the settlement, the company will cease opioid sales not just in New York state, but across the country.